| HOME >> BIOLOGY >> TECHNOLOGY |
compatible blood-forming cells), and to form adult red blood cells (for
people needing blood transfusions). In the area of regenerative
medicine, the Einstein Liver Center is conducting pioneering research
to cure liver diseases and inherited disorders such as hemophilia by
implanting cells that will multiply and restore patients' damaged or
diseased organs or tissues.
-- With some 20 of its scientists studying epigenomics, Einstein ranks as
a leader in this exciting new field, which the National Institutes of
Health recently added to research programs it funds that are "expected
to have exceptionally high impact." Epigenomics is the study of the
vast network of chemical "marks" inside our cells that control the
expression of our genes, turning them on and off at certain times and
in certain tissues. These chemicals, which latch onto our genes but can
also be removed, comprise our "epigenomes" and affect our lives in
crucially important ways. Scientists now believe that many complex
diseases, such as Alzheimer's and autism, result from epigenomic
changes that cause gene regulation to go awry. Altered epigenomic marks
have also been found in every type of cancer that researchers have
examined.
Dr. Greally, an internationally recognized expert in epigenomics and
head of the new Center for Epigenomics at Einstein, has developed a
novel method for "mapping" the most important epigenomic marks: the
methyl molecules present throughout a person's genome. He has used this
method to detect the methylation patterns that characterize breast
tumors and other types of cancers. Thanks to the resources that the new
epigenomics center offers, Dr. Greally and his colleagues can now
devise therapeutic strategies aimed at erasing the epigenomic mar
'/>"/>
| SOURCE The Albert Einstein College of Medicine of YeshivaUniversity Copyright©2008 PR Newswire. All rights reserved |